Search research articles
Contact Us
Filters
Showing results (41-50 of 56) with videos related to
Page
of 6
Sort By:
Frontiers in Oncology
|
September 26, 2024
Performance of PSMA-targeted radiotheranostics in an experimental model of renal cell carcinoma
Rajan Singh, Anand K Thotakura, Suresh Alati, et al.
JCO Precision Oncology
|
September 11, 2020
Comprehensive Genomic Analysis of Metastatic Non-Clear-Cell Renal Cell Carcinoma to Identify Therapeutic Targets
Maria I Carlo, Nabeela Khan, Ahmet Zehir, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 3, 2022
Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade
Yasser Ged, Alejandro Sanchez, Sujata Patil, et al.
Cancer
|
September 25, 2020
Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial
Darren R Feldman, Yasser Ged, Chung-Han Lee, et al.
Cancer Research Communications
|
March 29, 2024
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
Mark Yarchoan, John D Powderly, Bruno R Bastos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2021
Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma
Jack P Gleeson, Ines Nikolovski, Renzo Dinatale, et al.
Cancer Immunology Research
|
March 27, 2025
Anti-CTLA4 Therapy Leads to Early Expansion of a Peripheral Th17 Population and Induction of Th1 Cytokines
Mari Nakazawa, Soren Charmsaz, Elsa Hallab, et al.
Cancer Immunology Research
|
June 26, 2026
Peripheral Th17 immune signature associates with excellent response to anti-PD1/anti-PD-L1 therapy across solid tumors
Howard L Li, Soren Charmsaz, Chester Kao, et al.
Nature Communications
|
April 21, 2025
Age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitors
Chester Kao, Soren Charmsaz, Hua-Ling Tsai, et al.
Cancer Research Communications
|
September 15, 2025
Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy
Howard L Li, Soren Charmsaz, Mari Nakazawa, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 56) with videos related to
Sort By:
Page
of 6
Frontiers in Oncology
|
September 26, 2024
Performance of PSMA-targeted radiotheranostics in an experimental model of renal cell carcinoma
Rajan Singh, Anand K Thotakura, Suresh Alati, et al.
JCO Precision Oncology
|
September 11, 2020
Comprehensive Genomic Analysis of Metastatic Non-Clear-Cell Renal Cell Carcinoma to Identify Therapeutic Targets
Maria I Carlo, Nabeela Khan, Ahmet Zehir, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 3, 2022
Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade
Yasser Ged, Alejandro Sanchez, Sujata Patil, et al.
Cancer
|
September 25, 2020
Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial
Darren R Feldman, Yasser Ged, Chung-Han Lee, et al.
Cancer Research Communications
|
March 29, 2024
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
Mark Yarchoan, John D Powderly, Bruno R Bastos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2021
Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma
Jack P Gleeson, Ines Nikolovski, Renzo Dinatale, et al.
Cancer Immunology Research
|
March 27, 2025
Anti-CTLA4 Therapy Leads to Early Expansion of a Peripheral Th17 Population and Induction of Th1 Cytokines
Mari Nakazawa, Soren Charmsaz, Elsa Hallab, et al.
Cancer Immunology Research
|
June 26, 2026
Peripheral Th17 immune signature associates with excellent response to anti-PD1/anti-PD-L1 therapy across solid tumors
Howard L Li, Soren Charmsaz, Chester Kao, et al.
Nature Communications
|
April 21, 2025
Age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitors
Chester Kao, Soren Charmsaz, Hua-Ling Tsai, et al.
Cancer Research Communications
|
September 15, 2025
Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy
Howard L Li, Soren Charmsaz, Mari Nakazawa, et al.
Page
of 6